PhosImmune, Agenus deal

By WIR Staff | Jan 4, 2016 | 8:00 AM GMT

Agenus acquired cancer vaccine company PhosImmune for $2.5 million in

Read the full 102 word article

How to gain access

Continue reading with a
two-week free trial.